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Abstract
The maspin gene is not expressed in normal human
pancreas, but its expression is acquired during
human pancreatic carcinogenesis. In other normal
human cells and their malignant counterparts, maspin
expression is controlled through the epigenetic state
of its promoter. In studies presented herein, we used
bisulfite genomic sequencing and chromatin immu-
noprecipitation studies to show that maspin-negative
pancreas cells have a methylated maspin promoter,
and that the associated H3 and H4 histones are
hypoacetylated. In contrast to normal pancreas, four
of six human pancreatic carcinoma cell lines inves-
tigated displayed activation of maspin expression.
This activation of maspin expression in pancreatic
carcinoma cells was linked to demethylated pro-
moters and hyperacetylation of the associated H3
and H4 histones. In addition, 5-aza-2V-deoxycytidine
treatments activated maspin expression in the two
maspin-negative pancreatic carcinoma cell lines,
suggesting a causal role for cytosine methylation in
the maintenance of a transcriptionally silent maspin
gene. Thus, human pancreatic carcinoma cells ac-
quire maspin expression through epigenetic dere-
pression of the maspin locus, and in so doing appear
to co-opt a normal cellular mechanism for the
regulation of this gene.
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Introduction
The concept that DNA methylation might play in role in the
establishment and/or maintenance of tissue-specific gene
expression was first put forward by Holliday [1] and Riggs
[2]. Recently, we described an example of a human gene
that provides a strong evidence of this hypothesis [3]. This
gene, maspin (SERPINB5), is a member of the serpin
superfamily whose expression is regulated at the level of
transcription in a cell type–specific manner [3–5]. Most
epithelial cells display abundant an expression of maspin,
whereas mesenchymal cells do not express maspin, with the
notable exception of corneal stromal cells [6].
The loss ofmaspin expression appears to be an early event
in human breast carcinogenesis and can be detected even in
ductal carcinoma in situ [7]. Although the precise cellular and
biochemical activities of maspin are currently unknown, it has
been shown that forced reexpression of maspin, or exogenous
maspin protein, can inhibit certain characteristics of invasive
and malignant human breast carcinoma cell populations [4,8].
In other human cancers such as ovarian, lung, and pancreatic
cancers, maspin expression is gained in the carcinoma cells
compared to their normal cells of origin [9–12]. Because
maspin has a metastasis suppressor function in human breast
cells, the gain of expression observed in these other tumor
types is paradoxical.
Because the primary mechanism governing the loss of
maspin expression resides at the level of transcriptional
inactivation, much effort has been focused on understanding
what controls maspin transcriptional activity. Recent studies
directed toward understanding the transcriptional regulation
of maspin have revealed that epigenetic control is an impor-
tant mechanism that directs maspin mRNA expression
[3,13,14]. The epigenetic determinants associated with the
control of maspin expression occur in the 5V regulatory region
of the maspin gene and involve cytosine methylation, histone
acetylation, and chromatin architecture [3,13,14]. Interesting-
ly, these epigenetic differences participate in the normal cell
type–restricted expression of this gene and participate in the
establishment of the active versus repressed states of tran-
scriptional activity [3].
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We previously reported that maspin is aberrantly meth-
ylated and epigentically silenced in human breast carcino-
ma cells compared to normal human mammary epithelial
cells (HMECs) [13]. Recent reports indicate that, in contrast
to breast cancer, maspin expression is gained during pan-
creatic carcinogenesis; normal human pancreas is negative
for maspin expression [11,12]. However, during human
pancreatic carcinogenesis, transformed pancreatic cells
acquire maspin expression. Similar results have been
reported for maspin expression during ovarian carcinogen-
esis as well [9]. We hypothesized that the mechanism
underlying the gain of expression in human pancreatic
carcinoma cells is epigenetic in nature.
In this report, we demonstrate that gain of maspin ex-
pression in human pancreatic carcinoma cell lines is regu-
lated by the same epigenetic mechanisms, but in the
opposite direction, of maspin expression during breast car-
cinogenesis. Thus, whether or not maspin transcription is
silenced or activated during tumor progression of a specific
cell type, human tumor cells appear to co-opt a normal
mechanism to regulate the transcriptional activity of this
gene. Taken together, these results indicate that the cell
type–specific methylation pattern of the maspin promoter
that exists in normal nonexpressing cells can be replicated in
tumorigenic cells whose normal counterparts transcribe




Normal human pancreas cells were obtained from trans-
plant donors where the pancreas was considered unsuitable
for transplantation, or no recipient was available. Pancreatic
specimens were discarded and not used in this study if the
donor had any history of pancreatic disease. All specimens
were obtained at The University of Iowa Hospital and Clinics.
The protocol to use the normal human pancreas samples
was approved by The University of Iowa Institutional Review
Board for Human Subjects on February 12, 2001.
Cell Lines and Cell Culture
Normal HMECs were obtained from Clonetics (San
Diego, CA) and grown according to the manufacturer’s
instructions. The immortalized but nontumorigenic human
breast epithelial cell line MCF10A was obtained from the
American Type Culture Collection (Manassas, VA) and were
maintained in RPMI 1640 containing 10% fetal bovine serum
supplemented with 50 mg/ml gentamicin. All other human
breast cancer cell lines (MDA-MB-453, MDA-MB-157, MDA-
MB-468, MDA-MB-435, and MDA-MB-231) as well as hu-
man pancreatic carcinoma cell lines (BxPC3, AsPC-1,
Capan-1, Capan-2, MiaPaCa-2, and Panc-1) were obtained
from the American Type Culture Collection and were main-
tained in RPMI 1640 containing 10% fetal bovine serum
supplemented with 50 mg/ml gentamicin. For 5-aza-2V-deox-
ycytidine (5-aza-dC) reactivation studies in pancreatic can-
cer cell lines, cells were grown at low density in six-well
plates and were treated with 50 mM 5-aza-dC (Sigma, St.
Louis MO) in 1  phosphate-buffered saline on days 0 and
2. On day 4, total RNA was isolated from the different
treatment groups, and analyzed by reverse transcription
polymerase chain reaction (RT-PCR) as described below.
RT-PCR Assays for Gene Expression Analysis
Total cellular RNA was isolated using the Qiagen RNeasy
Mini Kit (Qiagen, Valencia, CA) and quantitated by absorp-
tion measurements at 260 nm. RT-PCR was performed
using RTG RT-PCR beads (Pharmacia, Piscataway, NJ).
To assess maspin expression, 250 ng of total RNA was
used, and to assess glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) expression, 125 ng of total RNA was used.
The RT reaction was primed with random hexamers and
incubated at 42jC for 1 hour followed by a chill at 4jC.
Maspin-specific PCR was performed by adding 25 pmol of
eachmaspinmRNA–specific primer prior to thermal cycling.
The maspin upstream primer is 5V-CTGACAACAGTGT-
GAACGAC-3 V and the downstream pr imer is 5 V-
CAAGCCTTGGGATCAATCATCT-3V, and correspond to nt
446 to 465 and nt 838 to 860 of themaspin cDNA (accession
no. NM002639). GAPDH expression was assessed using
GAPDH-specific primers obtained from R&D Systems (Min-
neapolis, MN). PCR conditions formaspin and GAPDH were
the same except that 35 cycles of PCR were performed for
maspin analysis and 32 cycles were performed for GAPDH.
The parameters used were: 95jC for 5 minutes followed by
the stated number of cycles of 94jC for 1 minute; 56jC for 30
seconds, and 72jC for 1 minute, ending with a final exten-
sion at 72jC for 5 minutes and a quick chill to 4jC. For
analysis, 20% of the respective PCR products was separat-
ed through a 3% agarose gel, stained with ethidium bromide,
and imaged using the Eagle Eye II Still Video System
(Stratagene, La Jolla, CA).
Sodium Bisulfite Genomic Sequencing of the Maspin
Promoter
Genomic DNA was isolated using the DNeasy Tissue Kit
(Qiagen) and quantitated spectrophotometrically. Five
micrograms of genomic DNA was modified with sodium
bisulfite under conditions previously described [15]. The
maspin promoter [16] was amplified from the bisulfite-mod-
ified DNA by two rounds of PCR using nested primers
specific to the bisulfite-modified sequence of the maspin
CpG island. The first-round primers are as follows: primer
U2, 5V-AAAAGAATGGAGATTAGAGTATTTTTTGTG-3V;
primer D2, 5V-CCTAAAATCACAATTATCCTAAAAAATA-3V.
The second-round primers are as follows: primer U3, 5V-
GAAATTTGTAGTGTTATTATTATTATA-3V; primer D3, 5V-
AAAAACACAAAAACCTAAATATAAAAA-3V. Both rounds of
PCRwere performed under the same parameters, with 1% of
the first-round PCR product serving as the template in the
second-round PCR. PCR amplification was performed under
the following conditions: 94jC for 4 minutes followed by five
cycles of 94jC for 1 minute, 56jC for 2 minutes, 72jC for 3
minutes, then 35 cycles of 94jC for 30 seconds, 56jC for 2
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minutes, 72jC for 1.5 minutes, and ending with a final
extension of 72jC for 6 minutes. The resultant PCR product
was cloned into a TA vector according to the manufacturer’s
instructions (pGEM-T-Easy cloning kit; Promega, Madison,
WI). Ten positive recombinants were isolated using a Qiap-
rep Spin Plasmid Miniprep Kit (Qiagen) according to the
manufacturer’s instructions and sequenced on an ABI auto-
mated DNA sequencer. The methylation status of individual
CpG sites was determined by comparison of the sequence
obtained with the known maspin sequence. The number of
methylated CpGs at a specific site was divided by the
number of clones analyzed (minimum of 10 in all cases) to
yield a percent methylation for each site.
Chromatin Immunoprecipitation Assays
Chromatin immunoprecipitations using the acetyl-histone
H3 and H4 antibodies were performed according to the
manufacturer’s instructions (Upstate Biotech, Lake Placid,
NY) with slight modifications [17]. Cells were rinsed in 1 
HBSS with 0.1% EDTA and treated with 1% formaldehyde
for 10 minutes at 37jC to form DNA–protein cross-links. The
cells were rinsed in ice-cold 1  HBSS with 0.1% EDTA
containing protease inhibitors (1 mM PMSF, 1 mg/ml aproti-
nin, 1 mg/ml pepstatin A), scraped, and collected by centri-
fugation at 4jC. Cells were then resuspended in a PIPES
buffer (5 mM PIPES pH 8.0, 85 mM KCl, 0.5% NP40)
containing protease inhibitors and incubated for 10 minutes
on ice. Cells were then collected by centrifugation and
resuspended in a sodium dodecyl sulfate lysis buffer con-
taining protease inhibitors and incubated on ice for 10
minutes. The DNA–protein complexes were sonicated to
lengths between 200 and 1000 bp as determined by gel
electrophoresis. Samples were centrifuged at 14,000 rpm at
4jC to spin out cell debris, then the supernatant was diluted
10-fold with ChIP dilution buffer containing protease inhib-
itors. One tenth of the sample was set aside for input control,
and the remaining sample was then precleared with either
Protein A Sepharose (Amersham Pharmacia Biotech, Pis-
cataway, NJ).
Following preclearing, the samples were split into thirds,
with two of the three samples treated with anti–acetyl-
histones H3 and H4, whereas the third sample was left as
minus antibody (Ab) control. All samples were rotated
overnight at 4jC. The chromatin–antibody complexes were
collected using Protein A Sepharose and then sequentially
washed with the manufacturer’s low-salt, high-salt, and LiCl
buffers, then twice with TE buffer (10 mM Tris–HCl, 1 mM
EDTA).
The chromatin–antibody complexes were eluted and the
DNA–protein cross-links were reversed with 400 mM NaCl
at 65jC for 4 hours for all samples, including the input DNA
control. All samples were treated with proteinase K, and the
acetyl-histone H3 and H4–enriched fractions of genomic
DNA were recovered by phenol/chloroform extractions and
ethanol precipitations, which were later quantitated using a
BioPhotometer (Eppendorf Scientific, Westbury, NY). Quan-
titative real-time PCR was used to analyze ChIP DNA, using
the ABI Prism 7000 sequence detector (Applied Biosystems,
Foster City, CA). PCR amplification of theMASPIN promoter
was done utilizing TaqMan primer/probes, whereas the
GAPDH promoter was amplified using conventional PCR
primers (primer sequences are available upon request).
Amplifications were done as outlined in Applied Biosystems,
TaqMan Universal PCR Master Mix, and SYBR Green PCR
Master Mix protocols forMASPIN andGAPDH, respectively.
MASPINwas amplified using the printed universal conditions
for 40 cycles, whereas GAPDH was amplified using the
following conditions; 95jC for 10 minutes followed by 40
cycles of 94jC for 1 minutes, and 68jC for 30 seconds, and
72jC for 1 minute.
For each experiment, the threshold bar was set within the
linear range of the PCR amplification. For the majority of the
experiments, the data were analyzed with the threshold set
at 0.1. The resulting Ct and Rn files were exported to Micro-
soft Excel for data and graphical analysis. Ct is the number of
PCR cycles necessary to reach fluorescence intensity (an
indirect measure of PCR product) within the linear range of
PCR amplification. Quantification was determined by apply-
ing the comparative Ct method, as described in the ABI 7000
sequence detection user guide and others. Briefly, fold
enrichment was calculated by subtracting the Ct value of
the ChIP DNA from the Ct value of the input DNA fraction,
and by using this value as the power that 2 is raised to (i.e.,
2Ct(Input)Ct(ChIP)).
Results
Normal Human Pancreas Cells Do Not Express Maspin
mRNA
Maspin mRNA was measured in normal human pancre-
as and HMECs by RT-PCR as shown in Figure 1A. The
human pancreas was previously shown to be negative for
maspin protein by immunohistochemistry [11] and our
findings that maspin mRNA is also undetectable in normal
human pancreas confirm and extend those earlier findings.
Maspin mRNA was abundantly expressed in normal
HMECs as has been previously described [4,13]. From
these expression patterns and from our previous experi-
ence with methylation-associated silencing of the maspin
gene in normal human tissues [3], we hypothesized that
CpG cytosines in the maspin promoter region would be
methylated in normal human pancreas. Figure 1B shows
histograms of CpG methylation across the maspin promot-
er regions in normal human breast and pancreas cells. In
breast cells that are maspin-positive, the promoter is
unmethylated as has been previously described [13],
whereas in maspin-negative pancreas cells, the promoter
is extensively methylated at all 19 CpG sites analyzed.
These findings are in precise agreement with the previ-
ously described role for DNA methylation in the cell type–
specific expression of maspin [3]. Figure 1C displays an
alternative representation of the distribution of methylated
cytosines in a number of clones to indicate that maspin is
not an imprinted locus in pancreas cells. These findings
support previous findings regarding the cell type–specific
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regulation of this genetic locus, and elucidate yet another
normal cell type (i.e., pancreas) wherein the genomic
methylation status of the maspin promoter was strictly
and inversely correlated with maspin mRNA expression.
Maspin Expression Is Acquired During Human Pancreatic
Carcinogenesis
Maass et al. first reported that human pancreatic cancer
cells showed increased maspin expression relative to
normal human pancreas [11]. This somewhat surprising
finding has fueled recent speculations as to the role of
maspin as a tumor suppressor [18]. Nevertheless, to
confirm and extend the findings by Maass et al., we
performed an RNA expression analysis on normal human
pancreas and six human pancreas carcinoma cell lines.
Our results, shown in Figure 2, indicate that although
maspin mRNA is undetectable in normal human pancreas,
four of six human pancreatic cancer cell lines examined
expressed maspin mRNA. All six of the pancreas carcino-
ma cell lines possess mutant p53 [19], which suggests that
although p53 has been shown to be a positive regulator of
maspin expression in human breast and prostate cells
[20,21], it is unlikely to be playing a part in maspin
expression among this panel of human pancreas cancer
cell lines. Thus, we sought to determine what other mech-
anisms could account for the acquisition of maspin mRNA
expression during pancreatic carcinogenesis.
The Maspin Promoter Becomes Unmethylated in Pancreatic
Carcinoma Cells That Have Acquired Maspin Expression
To test the hypothesis that demethylation of the maspin
promoter region could be responsible for the activation of
maspin expression seen in the human pancreatic cancer
cell lines, we performed bisulfite analysis on the maspin 5V
regulatory region in normal and malignant human pancreas
cells. The results of this experiment are shown in Figure 3,
and clearly indicate that the acquisition of maspin expres-
sion in the human pancreatic cancer cells is strictly corre-
lated with demethylation of the maspin promoter in these
cell lines. Whereas the maspin-negative pancreatic carci-
noma cells (Panc-1 and MiaPaCa) displayed a methylated
CpG pattern across the maspin promoter comparable to
Figure 1. Lack of maspin mRNA in normal pancreatic epithelial cells is tightly
associated with promoter methylation status. (A) RNA was isolated from
normal pancreas tissue and normal mammary cells (HMECs). RT-PCR was
performed for maspin mRNA expression and PCR products were visualized
by agarose gel electrophoresis and ethidium bromide staining. Normal
pancreas showed no maspin expression whereas normal mammary cells
showed robust maspin expression; -actin was used as a control. (B) DNA
from both tissues was sodium bisulfite –modified to determine the methyl-
ation status of the maspin promoter. Summary of 5-methylcytosine levels
obtained by sodium bisulfite genomic sequencing of the maspin promoter.
Cytosine methylation frequency histograms are shown for normal pancreas
and HMECs. The x-axis is nucleotide position relative to the transcription start
and the y-axis is the percent cytosine methylation. (C) Methylation status of
the individual alleles determined by bisulfite sequencing of cloned PCR
products. Each row of circles represents the cytosine methylation pattern
obtained from individual clones of the maspin promoter. The position of each
CpG site relative to transcription start is shown. Open circles indicate
unmethylated CpG sites; filled circles indicate methylated CpG sites.
430 Epigenetic Control of Maspin Expression in Human Cancer Fitzgerald et al.
Neoplasia . Vol. 5, No. 5, 2003
that seen in normal human pancreas, the maspin-positive
human pancreatic cancer cells were unmethylated in the
maspin promoter region. Figure 4 displays a different
representation of the distribution of methylated cytosines
in 10 sequenced clones from each cell line to indicate that
maspin is not an imprinted gene and that acquisition of
maspin expression is not allele-specific.
Maspin Expression Is Activated in Maspin-Negative Pan-
creatic Cancer Cells by 5-aza-dC, a DNA Demethylating
Agent
To test whether cytosine methylation in the maspin pro-
moter was functionally linked to its silencing in these human
pancreatic cancer cells, we treated the cells with 5-aza-dC, a
demethylating drug that has been shown to induce maspin
expression in human breast carcinoma cells as well as
maspin-negative human fibroblasts and kidney cells [3,13].
The maspin-negative Panc-1 and MiaPaCa cells were grown
for 4 days in the presence or absence of 50 mM 5-aza-dC and
then analyzed for maspin mRNA expression. Figure 5 shows
that 5-aza-dC caused a robust induction of maspin expres-
sion in both maspin-negative cell lines, further indicating the
importance of cytosine methylation in maintaining the tran-
scriptionally repressed state of maspin in maspin-negative
normal and tumor cell types.
Activation of Maspin Expression in Human Pancreatic
Cancer Cells Is Linked to Hyperacetylation of Histones H3
and H4 Associated with the Maspin Promoter
To assess whether chromatin structure at the maspin
promoter participates in the regulation of this gene, we
performed chromatin immunoprecipitation experiments with
Figure 3. Activation of maspin expression is associated with the demethylation of its promoter in pancreatic cancer cells. Bisulfite sequencing was used to analyze
cytosine methylation in six pancreatic cancer cell lines. The four unmethylated cell lines (AsPC-1, BxPC-3, Capan-2, and Capan-1) all showed activation of maspin
gene expression. In contrast, two maspin-negative cell lines (Panc-1 and MiaPaCA) were heavily methylated and exhibited no maspin expression. Summary of
5-methylcytosine levels obtained by sodium bisulfite genomic sequencing of the maspin promoter. Cytosine methylation frequency histograms are shown for
normal pancreas and HMECs. The x-axis is nucleotide position relative to the transcription start and the y-axis is the percent cytosine methylation.
 
Figure 2. Maspin expression is activated during pancreatic carcinogenesis.
RNA was isolated from normal pancreas tissues and six pancreatic cancer
cell lines, and RT-PCR was performed for maspin expression and -actin;
PCR products were visualized by agarose gel electrophoresis and ethidium
bromide staining. Maspin expression was gained in four of six pancreatic
carcinoma cell lines.
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antibodies directed against acetylated histones H3 and H4
and amplified the maspin promoter. The acetylation status of
these nucleosome constituents is tightly correlated to cyto-
sine methylation status and gene activity [22–24]. Thus, we
hypothesized that demethylated maspin-positive pancreatic
carcinoma cells would remodel their maspin promoter in an
active chromatin structure with hyperacetylated histones,
whereas the maspin-negative pancreas cells would maintain
their methylated maspin promoter in a chromatin structure
with hypoacetylated histones. Our results, shown in Figure 6,
indicate that the maspin promoter is associated with hypo-
acetylated histones in maspin-negative MiaPaCa pancreatic
cancer cells. However, the maspin promoter is associated
with hyperacetylated histones in maspin-positive BxPC3
human pancreatic cancer cells. These results suggest that
the maspin promoter becomes not only demethylated, but
the associated histones H3 and H4 become hyperacetylated
during the acquisition of maspin expression during pancre-
atic carcinogenesis. These findings provide further evidence
for strong epigenetic component to the regulation of this
gene in normal human tissues, and provide a likely mech-
anism for the gain of maspin expression observed in not only
Figure 4. Maspin promoter demethylation during transcriptional activation is not allele-specific. The methylation status of the individual alleles was determined by
bisulfite sequencing of 10 cloned PCR products. Each row of circles represents the cytosine methylation pattern obtained from an individual clone of the maspin
promoter. The position of each CpG site relative to transcription start is shown. Open circles indicate unmethylated CpG sites; filled circles indicate methylated CpG
sites.
Figure 5. Maspin expression can be activated in maspin-negative pancreatic
carcinoma cell lines with 5-aza-dC. Panc-1 and MiaPaCA cells lines with
methylated maspin promoters and no maspin expression were treated with
50 M 5-aza-dC for 48 hours. RNA was isolated, RT-PCR was performed,
and PCR products were visualized by agarose gel electrophoresis and
ethidium bromide staining.
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human pancreatic cancer, but also ovarian and lung cancers
[9–11], as well as the well-documented loss of maspin
expression in human breast cancer.
The Maspin Promoter Becomes Aberrantly Methylated
in Mammary Carcinoma Cells That Have Lost Maspin
Expression
The dense methylation of the maspin promoter seen in
normal maspin-negative normal pancreas tissues is similar
to the methylation state encountered in breast cancer cells
where the maspin gene is often silenced. As an example
and extension of cytosine methylation profiles obtained in
human breast cells, we show in Figure 7 the maspin-
positive nontumorigenic but immortalized HMEC line
MCF-10A, as well as the several additional human breast
cancer cell lines that have lost maspin expression in asso-
ciation with aberrant methylation of the maspin promoter.
Four of five of these human breast cancer cell lines showed
loss of maspin expression that was correlated without
exception to maspin promoter methylation. Only the MDA-
MB-468 human breast cancer cell line was maspin-positive
and its promoter was unmethylated. These results are
consistent with and extend previous reports indicating that
maspin inactivation in breast carcinogenesis is a frequent
event and that silencing of maspin expression is often
associated with aberrant cytosine methylation of the maspin
Figure 6. Histone acetylation state is linked to DNA methylation state at the maspin promoter in pancreatic cells. Acetylation of histones H3 (A) and H4 (B) in the
maspin and GAPDH promoters was analyzed using a quantitative chromatin immunoprecipitation assay. Gene promoter–specific real-time PCR was carried out
on DNA from the immunoprecipitated chromatin as well as input DNA. A representative real-time PCR graph and the fold enrichment of histone acetylation are
shown. Assessment of histone acetylation state of the ubiquitously expressed GAPDH was performed as a positive control.
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promoter. Taken together, these results indicate that the
cell type–specific methylation pattern of the maspin pro-
moter that exists in normal nonexpressing cells can be
replicated in tumorigenic cells whose normal counterparts
transcribe maspin, and that this methylation pattern is
associated with its transcriptional silencing.
Discussion
A critical mechanism that governs the differential transcrip-
tional activity of themaspin tumor suppressor gene in normal
human cells types is a transition in chromatin architecture
around the maspin promoter from an open and active state to
a heterochromatic state that is transcriptionally silentdddddd.
The structural changes in the maspin promoter leading to
gene silencing involve multiple enzyme-catalyzed modifica-
tions at the level of the nucleosome including cytosine
methylation by DNA methyltransferases (DNMTs) and his-
tone acetylation by histone acetyltransferases (HATs).
Overall, these indicators of chromatin structure are highly
predictive of the level of maspin expression within any
given human cell type; when the maspin promoter is
Figure 7. The loss of maspin expression in the majority of breast cancer cell lines is associated with aberrant methylation of its promoter. (A) RT-PCR was
performed on normal breast and five breast cancer cell lines not previously analyzed. Normal breast cells were maspin-positive, but four of five breast cancer cell
lines were maspin-negative, consistent with previous observations. (B) Bisulfite sequence analysis of maspin promoter methylation in normal breast cells and
breast cancer cells. Cytosine methylation histograms show that maspin promoter methylation in breast cancer cells is associated with the attenuation of maspin
expression.
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unmethylated and hyperacetylated, the gene is actively
expressed; however, when the maspin promoter is hyper-
methylated and hypoacetylated, the gene is not expressed.
These chromatin structural modifications have been dem-
onstrated as a major mechanism for the establishment
and/or maintenance of the maspin phenotype in many
types of normal human cells [3].
In breast cancer cells, this control is relaxed, producing
an epigenetic switch in the maspin promoter from an open
and on state to a closed and off state, resulting in the
silencing of maspin expression [13,21]. Surprising recent
work has found maspin expression to be activated in
certain forms of human cancers compared to the
corresponding normal cells from which they are presumed
to have arisen, and include pancreatic, ovarian, lung, and
gastric cancers [9–12,25]. We sought to determine if the
epigenetic switch at the maspin promoter in pancreatic
cancer worked from off to on, the direction opposite to
that seen in breast cancer, and to determine if this switch
was responsible for maspin activation. We chose to exam-
ine pancreatic cancers as they were among the first human
cancer types reported to display this paradoxical activation
of maspin expression [11].
Our analysis of human pancreatic cancer cells shows a
strict correlation between acquisition of maspin expression
and demethylation of the maspin promoter and hyperacety-
lation of the associated histones H3 and H4. In normal
maspin-negative pancreas cells, the maspin promoter was
densely methylated, whereas the epigenetic state (DNA
methylation and histone acetylation) of the maspin promoter
in the maspin-positive pancreatic cancer cells resembled the
state of the maspin promoter in normal maspin-positive cells
(e.g., HMECs). By comparison, in breast cancer cells, where
the maspin gene is inappropriately silenced, the epigenetic
state of the maspin promoter resembled that seen in normal
maspin-negative cells (e.g., pancreas). Together, these
results indicate that tumor cells can replicate the DNA
methylation and histone acetylation patterns specific to other
cell types, and that this epigenetic switch is tightly associated
with its transcriptional state.
The biological significance of increased maspin expres-
sion in pancreatic carcinoma cells and other human cancers
where maspin is activated is unclear. Nevertheless, these
reports have challenged the role of maspin as a tumor
suppressor and/or suppressor of metastasis; however, it
should be pointed out that these were correlative studies
where a role for maspin in the disease process was not
determined. In contrast, direct functional studies in breast
cancer cells have clearly shown that maspin suppresses
aggressive tumor characteristics, such as cell adhesion,
motility, and angiogenic properties [4,26–28].
Thus, whether maspin activation is a participant in the
carcinogenic process in pancreatic cancer, or whether it is a
bystander event is unknown. The loss of maspin promoter
methylation may be a nonspecific alteration that accompa-
nies the complex and genome-wide epigenetic changes that
occur in the genomes of cancer cells [29,30], and therefore
may provide no selective advantage to the cancer cell.
Another possible explanation for these apparently contradic-
tory results is that the maspin protein has different functions
in different cell types depending on the spectrum of other
maspin interacting proteins that are expressed within a given
cell type or its surroundings. Finally, the subcellular localiza-
tion of maspin may play a critical role in determining its
function. Indeed, there have been recent reports that maspin
is expressed in the nuclei of certain cell types [31]. Whether
this inappropriate activation of maspin expression imparts
any significant phenotypic changes on the tumor, or whether
its activation is an epiphenomenon that reflects loss of
methylation homeostasis remains to be determined.
In summary, we show that pancreatic cancer cells ac-
quire maspin expression through demethylation of the mas-
pin promoter and hyperacetylation of the associated
histones. These results show that the maspin promoter in
pancreatic cancer cells undergoes an epigenetic switch
from the off to on position. In comparison, breast cancer
cells undergo a switch from on to off at the same locus. In
both cases, the maspin promoter took on the epigenetic
appearance of a different normal cell type. We speculate
that the same epigenetic mechanisms that control maspin
expression in normal cell types are co-opted during carci-
nogenesis. This view would be consistent with current
concepts of the plasticity of the differentiated state, the
overall and regional states of differentiation within a tumor
(i.e., well differentiated or poorly differentiated), and the
nature of the mechanisms underlying changes in gene
expression patterns during transdifferentiation, including
epithelial–mesenchymal transition [32,33].
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